Skip to main content
. 2016 Feb 11;31(1):22–28. doi: 10.1038/jhh.2015.124

Table 2. Incidence rates and 95%CI of hypertension according to population characteristics at baseline.

  Rural group Migrant group Urban group
Sex
 Female 2.65 (1.57–4.48) 2.14 (1.46–3.14) 1.72 (0.77–3.83)
 Male 2.17 (1.13–4.18) 0.97 (0.52–1.80) 0.35 (0.05–2.52)
 
Age
 30–49 years 1.98 (1.12–3.49) 1.07 (0.65–1.77) 0.95 (0.36–2.54)
 50+ years 3.27 (1.81–5.91) 2.49 (1.62–3.82) 1.42 (0.46–4.39)
 
Education level
 None/some primary school 2.23 (1.30–3.85) 2.48 (1.52–4.05)
 Complete primary 2.47 (0.93–6.58) 1.36 (0.56–3.26) 2.22 (0.31–15.78)
 Some secondary 3.03 (1.36–6.75) 1.22 (0.74–2.03) 1.10 (0.49–2.45)
 
Socioeconomic status
 Lowest tertile 1.95 (1.08–3.52) 1.57 (0.93–2.65) 1.82 (0.68–4.84)
 Middle tertile 1.52 (0.21–10.76) 1.96 (1.11–3.45) 0.53 (0.075–3.76)
 Highest tertile 3.53 (1.95–6.37) 1.35 (0.73–2.50) 0.90 (0.23–3.60)
 
Binge drinking
 No 2.42 (1.56–3.74) 1.68 (1.21–2.34) 1.22 (0.58–2.55)
 Yes 2.63 (0.85–8.16) 0.60 (0.08–4.25)
 
Daily smoking
 No 2.35 (1.55–3.57) 1.65 (1.19–2.28) 1.18 (0.56–2.48)
 Yes 16.67 (2.35–118.32)
 
Physical activity
 Moderate/high levels 2.47 (1.64–3.72) 1.67 (1.14–2.45) 1.32 (0.55–3.18)
 Low levels 1.52 (0.82–2.82) 0.79 (0.20–3.16)
 
Total cholesterol
 <200 mg dl−1 2.18 (1.39–3.42) 1.31 (0.84–2.06) 1.02 (0.38–2.73)
 ⩾200 mg dl−1 5.56 (2.09–14.80) 2.13 (1.32–3.42) 1.25 (0.40–3.88)
 
High waist circumference
 No 2.05 (1.26–3.35) 0.89 (0.45–1.79) 0.41 (0.06–2.93)
 Yes 4.67 (2.22–9.79) 2.08 (1.44–3.01) 1.56 (0.70–3.48)
 
Obesity
 BMI <30 kg m2 2.32 (1.51–3.55) 1.45 (0.99–2.13) 0.45 (0.11–1.82)
 BMI ⩾30 kg m−2 5.56 (1.39–22.21) 2.19 (1.18–4.07) 2.62 (1.09–6.29)
 
Type 2 diabetes
 No 2.47 (1.64–3.72) 1.52 (1.08–2.14) 0.85 (0.35–2.05)
 Yes 3.95 (1.27–12.24) 4.55 (1.14–18.17)
 
Pre-hypertension
 No 1.74 (0.93–3.23) 0.99 (0.58–1.67) 0.76 (0.24–2.34)
 Yes 3.55 (2.06–6.12) 2.66 (1.75–4.04) 1.71 (0.64–4.55)

Abbreviations: BMI, body mass index; CI, confidence interval. Incidence rate was not calculated as there were no hypertension cases during follow-up (—).